Akari Therapeutics Plc AKTX

Latest FY: 2025 Healthcare Biotechnology
Market Price $10.27
Market Cap $992.59B
P/E Ratio N/A
Quick Peer Compare (Healthcare):
Revenue (FY 2025)
N/A
Full year reported
Net Income ↑12.6% YoY
-$17.30M
Net Margin: N/A
Free Cash Flow
-$10.57M
FCF Yield: -0.00%
EPS (Diluted)
N/A
Basic: N/A
Return on Equity Efficiency
-61.1%
ROA: -36.1%

📊 Multi-Year Historical Performance & Trends

Financial Performance History Revenue, Net Income & Free Cash Flow
Margins Trend (%) Gross, Operating & Net Margins
Balance Sheet Strength Cash, Debt & Equity
Cash Flow Generation Operating Cash Flow vs CapEx vs FCF

📈 Year-over-Year (YoY) Growth History (AKTX)

All monetary values in millions ($M)
⚠️ YoY Data Quality Alert
  • FY 2017: Revenue YoY (+22.5%) is identical to Gross Profit YoY (+22.5%). Verify the underlying Revenue and Gross Profit values for FY 2017 and FY 2016.
  • FY 2018: Revenue YoY (+26.7%) is identical to Gross Profit YoY (+26.7%). Verify the underlying Revenue and Gross Profit values for FY 2018 and FY 2017.
  • FY 2019: Revenue YoY (-97.5%) is identical to Gross Profit YoY (-97.5%). Verify the underlying Revenue and Gross Profit values for FY 2019 and FY 2018.
  • FY 2020: Revenue YoY (+146.2%) is identical to Gross Profit YoY (+146.2%). Verify the underlying Revenue and Gross Profit values for FY 2020 and FY 2019.
  • FY 2021: Revenue YoY (-22.1%) is identical to Gross Profit YoY (-22.1%). Verify the underlying Revenue and Gross Profit values for FY 2021 and FY 2020.
  • FY 2022: Revenue YoY (+333.4%) is identical to Gross Profit YoY (+333.4%). Verify the underlying Revenue and Gross Profit values for FY 2022 and FY 2021.
Fiscal Year Revenue Revenue YoY Gross Profit Net Income Net Inc YoY Diluted EPS EPS YoY Div / Sh Div Yield Op. Cash Flow Free Cash Flow FCF YoY
FY 2016 $0.1M $0.1M $-18.1M $-24.6M $-24.7M
FY 2017 $0.2M +22.5% $0.2M $-35.4M -95.1% $-31.6M $-31.6M -28.2%
FY 2018 $0.2M +26.7% $0.2M $-16.5M +53.5% $-22.6M $-22.6M +28.6%
FY 2019 $0.0M -97.5% $0.0M $-17.1M -3.9% $-0.01 $-12.9M $-12.9M +42.8%
FY 2020 $0.0M +146.2% $0.0M $-17.1M +0.1% $-0.01 0.0% $-17.0M
FY 2021 $0.0M -22.1% $0.0M $-17.4M -2.0% +100.0% $-18.8M
FY 2022 $0.0M +333.4% $0.0M $-17.7M -1.9% $-21.5M
FY 2023 -100.0% $-10.0M +43.6% $-16.4M
FY 2024 $-19.8M -97.8% $-12.6M
FY 2025 $-17.3M +12.6% $-10.6M
$

Valuation

Market Price $10.27
Market Cap $992.59B
Enterprise Value $992.59B
P/E Ratio N/A
P/B Ratio 33,196.60
FCF Yield -0.00%
Dividend Yield 0.00%
Shares Outstanding 91,567,009,533
%

Profitability & Margins

Gross Margin N/A
Operating Margin N/A
Net Margin N/A
Return on Equity (ROE) -61.06%
Return on Assets (ROA) -36.12%
Asset Turnover N/A
Revenue 3-Yr CAGR N/A
🛡️

Financial Health & Liquidity

Current Ratio 0.44
Cash Ratio 0.00
Debt / Equity 0.000
Debt / Assets 0.000
Cash & Equivalents N/A
Total Debt N/A
Book Value / Share $0.00
💧

Cash Flow Efficiency

Operating Cash Flow -$10.57M
Capital Expenditures (CapEx) N/A
Free Cash Flow -$10.57M
OCF / Revenue N/A
FCF / Revenue N/A
FCF 3-Yr CAGR N/A
🏷️

Per Share Metrics

EPS (Diluted) N/A
EPS (Basic) N/A
Dividends / Share N/A
Book Value / Share $0.00
EPS YoY Growth N/A
🏛️

Balance Sheet (FY 2025)

Total Assets $47.89M
Total Liabilities $19.56M
Stockholders' Equity $28.33M
Current Assets $5.46M
Current Liabilities $12.35M